Literature DB >> 3994563

Phenytoin disposition in obesity. Determination of loading dose.

D R Abernethy, D J Greenblatt.   

Abstract

Fourteen obese subjects (mean body weight, 124 kg; percent of ideal body weight [IBW], 178%) and ten control subjects of normal body habitus (mean body weight, 67 kg; 92% IBW) received 300 mg of phenytoin sodium by ten-minute intravenous infusion. Obese subjects compared with controls had prolonged phenytoin elimination half-life (19.9 v 12.0 hours). Total metabolic clearance of phenytoin was greater in obese than in control groups, although the difference was not significant (59 v 39 mL/min). Phenytoin half-life, inversely proportional to clearance and directly proportional to volume of distribution (Vd), was prolonged in obesity mainly as a result of the increase in Vd in obese subjects (84 v 40 L). Phenytoin loading dose should be calculated on the basis of IBW plus the product of 1.33 times the excess weight over IBW. Very obese individuals will require large absolute loading doses of phenytoin to rapidly achieve therapeutic drug concentrations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994563     DOI: 10.1001/archneur.1985.04060050066010

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  20 in total

Review 1.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Body mass index and weight gain as alternative or complementary hypothesis to explain olanzapine concentration-dose ratio accumulation.

Authors:  Bruno Charpiat
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 3.  Drug-Nutrition Interactions and the Brain: It's Not All in Your Head.

Authors:  Joseph I Boullata
Journal:  Curr Nutr Rep       Date:  2019-06

Review 4.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

5.  Pharmacokinetics and drug dosing in obese children.

Authors:  Jennifer G Kendrick; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

6.  Phenobarbital pharmacokinetics in obesity. A case report.

Authors:  L Wilkes; L H Danziger; K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

7.  Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study.

Authors:  S Vozeh; T Uematsu; L Aarons; P Maitre; H Landolt; O Gratzl
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

Review 8.  Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.

Authors:  Jennifer H Martin; Mohamed Saleem; David Looke
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

Review 9.  Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.

Authors:  Claudia Langebrake; Friederike Bernhardt; Michael Baehr; Nicolaus Kröger; Axel R Zander
Journal:  Int J Clin Pharm       Date:  2011-09-29

Review 10.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.